某院静脉输注抗肿瘤药说明书使用事项标注情况分析

doi:10.19803/j.1672-8629.2021.10.18

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (10): 978-980.
DOI: 10.19803/j.1672-8629.2021.10.18

某院静脉输注抗肿瘤药说明书使用事项标注情况分析

赵爽, 古瑞, 宋燕青, 王向峰, 苗秋丽^*

吉林大学第一医院药学部,吉林长春 130021

收稿日期:2020-01-20 出版日期:2021-10-15 发布日期:2021-10-27
通讯作者: ^*苗秋丽,硕士,主管药师,肿瘤临床药学。E-mail：miaoql365@163.com
作者简介:赵爽,女,硕士,主管药师,肿瘤临床药学。

Information Labeling in Instructions of Anti-tumor Drugs for Intravenous Infusion in a Hospital

ZHAO Shuang, GU Rui, SONG Yanqing, WANG Xiangfeng, MIAO Qiuli^*

Department of Pharmacy, the First Hospital of Jilin University, Changchun Jilin 130021, China

Received:2020-01-20 Online:2021-10-15 Published:2021-10-27

摘要/Abstract

摘要： 目的分析静脉输注抗肿瘤药说明书使用事项标注情况,为合理规范使用抗肿瘤药提供参考。方法收集某院静脉输注抗肿瘤药药品说明书,对说明书中的相关标注信息情况是否完整进行统计,分析目前静脉输注抗肿瘤药说明书信息标注情况及存在问题。结果 91份静脉输注抗肿瘤药说明书中,输注前标注信息情况中,预处理8份。输注过程中说明书标注情况,输液器具5份（5.49%）、冲管2份（2.20%）、输液稳定性8份（8.79%）、输注过程中是否需要监护15份（16.48%）和说明具体抢救措施13份（14.29%）。结论 91份静脉输注抗肿瘤药说明书中标注项目缺失严重,应加强完善与修改,对各项内容进行规范性标注。

关键词: 药品说明书, 标注信息, 抗肿瘤药, 静脉输注

Abstract: Objective To investigate the problems with information labeling in instructions of antineoplastic drugs for intravenous infusion in order to provide reference for the rational use of antineoplastic drugs. Methods The instructions of anti-tumor drugs for intravenous infusion were collected from a hospital, the completeness of information in the instructions was statistically analyzed, and problems with the instructions of anti-tumor drugs for intravenous infusion were investigated. Results Among the ninety-one instructions of antineoplastic drugs for intravenous infusion, there were eight (7.41%) that involved pre-treatment. There were five instructions (5.49%) involving infusion instruments, two (2.20%) involving flushing tubes, eight involving (8.79%) infusion stability, fifteen (16.48%) involving the need for monitoring during infusion and thirteen involving (14.29%) rescue measures. Conclusion The information labeled in the 91 instructions of anti-tumor drugs for intravenous infusion is seriously inadequate. Therefore, it is necessary to revise the instructions, and standardize information labeling in drug instructions.

Key words: drug instruction, labeling information, antineoplastic drug, intravenous infusion

中图分类号:

R979.1

赵爽, 古瑞, 宋燕青, 王向峰, 苗秋丽. 某院静脉输注抗肿瘤药说明书使用事项标注情况分析[J]. 中国药物警戒, 2021, 18(10): 978-980.

ZHAO Shuang, GU Rui, SONG Yanqing, WANG Xiangfeng, MIAO Qiuli. Information Labeling in Instructions of Anti-tumor Drugs for Intravenous Infusion in a Hospital[J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 978-980.

参考文献

[1] Yuan CM.Analysis and research on adverse reactions of antineoplastic drugs[J]. Chinese Prescription Drugs(中国处方药), 2019, 17(9): 23-24.
[2] Yang F, Wang D.Analysis and prevention of adverse reactions of antineoplastic drugs[J]. Capital Food and Medicine(首都食品与医药), 2019, 26(19): 79.
[3] Wang YQ, Li YZ, Zhen JC.Basic skills and practice of hospital pharmacists(医院药师基本技能与实践)[M]. Beijing: People’s Health Publishing House, 2013.
[4] State Food and Drug Administration. Regulations on the administration of drug instructions and labels[EB/OL]. (2006-03-16) [2019-12-20].. Regulations on the administration of drug instructions and labels[EB/OL]. (2006-03-16) [2019-12-20]. http://www.gov.cn/ziliao/flfg/2006-03/16/content_228465.htm.
[5] State Food and Drug Administration. Notice on printing and distributing detailed rules for specification of chemical and biological products[EB/OL]. (2006-05-10) [2019-12-20]. http://www.nmpa.gov.cn/WS04/CL2196/323547.html.
[6] Matthew P.Management of digoxin toxicity[J]. Australian Prescriber, 2016, 39(1): 18-20.
[7] Jing YY.Analysis of 105 cases of new serious adverse drug reactions caused by intravenous drip[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2010, 7(4): 240-242.
[8] Wu YP, Jiao YH.Guidelines for Clinical Intravenous Drug Use(临床静脉用药调配和使用指南) [M]. Beijing: People’s Health Publishing House, 2010.
[9] Zhang X, Niu J, Wu XY.Pareto diagram analysis of irrational drug use prescriptions in pharmacy intravenous admixture service[J]. Chinese Journal of Pharmacovigilance, 2017, 14(3): 183-185.
[10] Wang YL.Investigation and analysis of 40 groups of injection drug instructions in our hospital[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018,15(3): 147-168.
[11] Cheng J, Gong XY, Li CH.Investigation and analysis of intravenous infusion of antineoplastic drugs in a hospital[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2016, 36(24): 2213-2217.
[12] Wang XJ, Fan XC, Li DN.Intervention and analysis of irrational use of cytotoxic drugs[J]. Journal of Guangdong Pharmaceutical University(广东药科大学学报), 2018, 34(6): 112-115, 119.
[13] Yang YQ, Pei BX, Liang X, et al.Analysis of irrational medical orders in the venous allocation center of tumor pharmacy in our hospital[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2012, 9(3): 160-162.
[14] Li W, Tang F.Analysis and discussion on the method of anti-tumor drug order audit[J]. Modern Medicine and Health(现代医药卫生), 2015, 31(2): 310-312.
[15] Wang HY, Zhang HF.Analysis of irrational use of antineoplastic drugs in inpatients of our hospital in the first half of 2015[J]. Drug Evaluation(药品评价), 2016, 13(4): 44-47.

某院静脉输注抗肿瘤药说明书使用事项标注情况分析

Information Labeling in Instructions of Anti-tumor Drugs for Intravenous Infusion in a Hospital

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	张建, 方慧华. 某院活血化瘀类中药注射剂使用评价标准建立的探索[J]. 中国药物警戒, 2024, 21(2): 185-189.
[2]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[3]	熊玮仪, 任经天. 抗肿瘤药说明书安全性信息上市后修订的考虑要点[J]. 中国药物警戒, 2024, 21(1): 94-97.
[4]	李容容, 李盟, 苟悦, 罗琼, 吕桦, 孙鑫, 刘成海. 113例抗肿瘤药物相关肝损伤的临床特点及危险因素分析[J]. 中国药物警戒, 2023, 20(5): 505-510.
[5]	罗世书, 屈杰, 周楠, 徐翠香, 刘屹, 张丽洁, 王建华. 289例单克隆抗体抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(4): 444-448.
[6]	杨岩, 周德喜, 吴欣俐, 薛淑雅, 丁海华, 张泉, 张云玲. 84例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(3): 334-338.
[7]	姚鑫, 葛秋格, 李亚敏, 王一帆, 李媛媛, 刘志强. 2018~2022年某院新型抗肿瘤药物消化系统不良反应分析[J]. 中国药物警戒, 2023, 20(11): 1273-1278.
[8]	张青霞, 江永贤, 董月鑫, 咸颖, 闫素英. 某三甲医院西药药品说明书贮藏条件风险分析及防范建议[J]. 中国药物警戒, 2022, 19(8): 913-918.
[9]	邰新娟, 马洪凤, 李君, 马维兴, 闫亚卫. 400例抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2022, 19(5): 541-544.
[10]	肖望重, 林聪, 黄莉, 戴冰, 高元峰. 中成药说明书用药禁忌调查分析[J]. 中国药物警戒, 2022, 19(4): 400-403.
[11]	赵建彬, 黄玉玲. 基于药品说明书和裁判文书的注射用帕瑞昔布用药风险点探索及应用[J]. 中国药物警戒, 2022, 19(11): 1250-1253.
[12]	何璇, 王晓, 戴惠珍, 李歆, 韩峰. 2018年~2020年南京地区新型抗肿瘤药物利用分析[J]. 中国药物警戒, 2021, 18(8): 725-730.
[13]	曹兆流, 张玮, 乔洋, 马宇昊, 韩峰, 李歆. 国内外抗肿瘤药物经济学评价文献计量学研究[J]. 中国药物警戒, 2021, 18(8): 737-742.
[14]	张永恒, 韩晨, 杨宵, 韩秀奇, 袁红昌, 邓智建. 313份注射液药品说明书标注信息调查分析[J]. 中国药物警戒, 2021, 18(7): 669-673.
[15]	王江流, 刘平羽, 李歆, 韩峰. 基于比价分析法探讨抗肿瘤药物价格合理性[J]. 中国药物警戒, 2021, 18(12): 1162-1165.